Product Description
Belapectin (GR-MD-02) is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer comprising galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. Structural studies have shown that belapectin binds to galectin-1 and galectin-3, with greater binding affinity to galectin-3. Belapectin targets extracellular galectins.
Mechanisms of Action: GAL3 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Galectin
Company Location: NORCROSS GA 30071
Company CEO: Joel Lewis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, Canada, Chile, France, Germany, Israel, Korea, Mexico, Poland, Puerto Rico, Spain, United Kingdom, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Esophageal and Gastric Varices|Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Liver Cirrhosis|Liver Cirrhosis, Alcoholic|Non-alcoholic Steatohepatitis|Varicose Veins
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GT-031 | P3 |
Unknown Status |
Liver Cirrhosis|Non-alcoholic Steatohepatitis |
2028-01-14 |
|
| NAVIGATE | P3 |
Active, not recruiting |
Varicose Veins|Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis|Esophageal and Gastric Varices|Liver Cirrhosis, Alcoholic|Hepatitis, Alcoholic |
2024-12-01 |
41% |
| NASH-RX | P3 |
Active, not recruiting |
Liver Cirrhosis|Non-alcoholic Steatohepatitis |
2023-09-11 |
|
| GT-032 | P1 |
Completed |
Healthy Volunteers |
2022-03-09 |
21% |